Health technology assessment and its role in the future development of the Indian healthcare sector.

PubWeight™: 1.11‹?› | Rank: Top 10%

🔗 View Article (PMC 3371551)

Published in Perspect Clin Res on April 01, 2012

Authors

Bastian Hass1, Jayne Pooley, Martin Feuring, Viraj Suvarna, Adrian E Harrington

Author Affiliations

1: Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany.

Articles cited by this

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Household catastrophic health expenditure: a multicountry analysis. Lancet (2003) 20.07

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Reduction of catastrophic health care expenditures by a community-based health insurance scheme in Gujarat, India: current experiences and challenges. Bull World Health Organ (2002) 6.81

Catastrophic payments for health care in Asia. Health Econ (2007) 5.16

Chronic diseases and injuries in India. Lancet (2011) 4.27

Financing health care for all: challenges and opportunities. Lancet (2011) 3.93

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06

Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ (2008) 2.43

Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med (2010) 2.11

Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke (1999) 1.72

Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology (2003) 1.69

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost (2011) 1.59

Health insurance benefit packages prioritized by low-income clients in India: three criteria to estimate effectiveness of choice. Soc Sci Med (2006) 1.28

Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. Pharmacoeconomics (2009) 1.23

The greatest happiness of the greatest number? Policy actors' perspectives on the limits of economic evaluation as a tool for informing health care coverage decisions in Thailand. BMC Health Serv Res (2008) 1.21

Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand. Cost Eff Resour Alloc (2006) 1.12

Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? Value Health (2010) 1.06

Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff (Millwood) (2008) 0.91

Articles by these authors

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45

Nongenomic steroid action: controversies, questions, and answers. Physiol Rev (2003) 2.41

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis (2012) 1.63

Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thromb Res (2012) 0.88

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol (2012) 0.88

Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging. J Biol Chem (2008) 0.87

Porcine spermatozoa contain more than one membrane progesterone receptor. Int J Biochem Cell Biol (2004) 0.86

Early aldosterone up-regulated genes: new pathways for renal disease? Kidney Int (2003) 0.83

Acute effects of aldosterone on intracardiac monophasic action potentials. Int J Cardiol (2002) 0.83

Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids (2002) 0.83

Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly. Cytokine (2008) 0.82

Non-genomic aldosterone action: from the cell membrane to human physiology. J Steroid Biochem Mol Biol (2002) 0.82

Effects of synthetic progestagens on autonomic tone, neurohormones and C-reactive protein levels in young healthy females in reproductive age. Int J Cardiol (2005) 0.82

Nongenomic cardiovascular effects of triiodothyronine in euthyroid male volunteers. J Clin Endocrinol Metab (2002) 0.82

Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res (2012) 0.82

Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost (2015) 0.80

Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost (2016) 0.80

Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting. Value Health (2008) 0.79

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials. Thromb J (2012) 0.79

Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J (2012) 0.78

Novel approaches in the treatment of allergic rhinitis. Curr Opin Allergy Clin Immunol (2003) 0.77

Modular, self-assembling peptide linkers for stable and regenerable carbon nanotube biosensor interfaces. J Mol Recognit (2006) 0.76

Structure-based rationale for interleukin 5 receptor antagonism. Curr Pharm Des (2008) 0.76

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost (2017) 0.75

A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α. Biochemistry (2011) 0.75

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost (2015) 0.75